210 related articles for article (PubMed ID: 38566132)
1. Conserved methylation signatures associate with the tumor immune microenvironment and immunotherapy response.
Qin Q; Zhou Y; Guo J; Chen Q; Tang W; Li Y; You J; Li Q
Genome Med; 2024 Apr; 16(1):47. PubMed ID: 38566132
[TBL] [Abstract][Full Text] [Related]
2. Genome-wide DNA methylation profile identified a unique set of differentially methylated immune genes in oral squamous cell carcinoma patients in India.
Basu B; Chakraborty J; Chandra A; Katarkar A; Baldevbhai JRK; Dhar Chowdhury D; Ray JG; Chaudhuri K; Chatterjee R
Clin Epigenetics; 2017; 9():13. PubMed ID: 28174608
[TBL] [Abstract][Full Text] [Related]
3. Molecular, clinicopathological, and immune correlates of LAG3 promoter DNA methylation in melanoma.
Fröhlich A; Sirokay J; Fietz S; Vogt TJ; Dietrich J; Zarbl R; Florin M; Kuster P; Saavedra G; Valladolid SR; Hoffmann F; Flatz L; Ring SS; Golletz C; Pietsch T; Strieth S; Brossart P; Gielen GH; Kristiansen G; Bootz F; Landsberg J; Dietrich D
EBioMedicine; 2020 Sep; 59():102962. PubMed ID: 32861198
[TBL] [Abstract][Full Text] [Related]
4. LRRC3B and its promoter hypomethylation status predicts response to anti-PD-1 based immunotherapy.
Luo L; Fu S; Du W; He LN; Zhang X; Wang Y; Zhou Y; Hong S
Front Immunol; 2023; 14():959868. PubMed ID: 36798137
[TBL] [Abstract][Full Text] [Related]
5. Use of Novel m6A Regulator-mediated Methylation Modification Patterns in Distinct Tumor Microenvironment Profiles to Identify and Predict Glioma Prognosis and Progression, T-cell Dysfunction, and Clinical Response to ICI Immunotherapy.
Zhao B; Xiang Z; Wu B; Zhang X; Feng N; Wei Y; Zhang W
Curr Pharm Des; 2023; 29(1):60-78. PubMed ID: 36503445
[TBL] [Abstract][Full Text] [Related]
6. Hypomethylation coordinates antagonistically with hypermethylation in cancer development: a case study of leukemia.
Kushwaha G; Dozmorov M; Wren JD; Qiu J; Shi H; Xu D
Hum Genomics; 2016 Jul; 10 Suppl 2(Suppl 2):18. PubMed ID: 27461342
[TBL] [Abstract][Full Text] [Related]
7. Genome-wide DNA methylation profile analysis identifies an individualized predictive signature for melanoma immune response.
Yan J; Wu X; Zhu Y; Cang S
J Cancer Res Clin Oncol; 2023 Jan; 149(1):343-356. PubMed ID: 36595044
[TBL] [Abstract][Full Text] [Related]
8. DNA methylome in pancreatic cancer identified novel promoter hyper-methylation in NPY and FAIM2 genes associated with poor prognosis in Indian patient cohort.
Chatterjee A; Bararia A; Ganguly D; Mondal PK; Roy P; Banerjee S; Ghosh S; Gulati S; Ghatak S; Chattopadhay BK; Basu P; Chatterjee A; Sikdar N
Cancer Cell Int; 2022 Nov; 22(1):334. PubMed ID: 36329447
[TBL] [Abstract][Full Text] [Related]
9. Genome-wide methylomic and transcriptomic analyses identify subtype-specific epigenetic signatures commonly dysregulated in glioma stem cells and glioblastoma.
Pangeni RP; Zhang Z; Alvarez AA; Wan X; Sastry N; Lu S; Shi T; Huang T; Lei CX; James CD; Kessler JA; Brennan CW; Nakano I; Lu X; Hu B; Zhang W; Cheng SY
Epigenetics; 2018; 13(4):432-448. PubMed ID: 29927689
[TBL] [Abstract][Full Text] [Related]
10. Multi-omics analysis of tumor angiogenesis characteristics and potential epigenetic regulation mechanisms in renal clear cell carcinoma.
Zheng W; Zhang S; Guo H; Chen X; Huang Z; Jiang S; Li M
Cell Commun Signal; 2021 Mar; 19(1):39. PubMed ID: 33761933
[TBL] [Abstract][Full Text] [Related]
11. Exploring targets of TET2-mediated methylation reprogramming as potential discriminators of prostate cancer progression.
Kamdar S; Isserlin R; Van der Kwast T; Zlotta AR; Bader GD; Fleshner NE; Bapat B
Clin Epigenetics; 2019 Mar; 11(1):54. PubMed ID: 30917865
[TBL] [Abstract][Full Text] [Related]
12. Oncogenic signaling pathway-related long non-coding RNAs for predicting prognosis and immunotherapy response in breast cancer.
Li H; Liu H; Hao Q; Liu X; Yao Y; Cao M
Front Immunol; 2022; 13():891175. PubMed ID: 35990668
[TBL] [Abstract][Full Text] [Related]
13. Lowly methylated region analysis identifies EBF1 as a potential epigenetic modifier in breast cancer.
Fernandez-Jimenez N; Sklias A; Ecsedi S; Cahais V; Degli-Esposti D; Jay A; Ancey PB; Woo HD; Hernandez-Vargas H; Herceg Z
Epigenetics; 2017; 12(11):964-972. PubMed ID: 29099283
[TBL] [Abstract][Full Text] [Related]
14. Integrating single-cell and bulk RNA sequencing data unveils antigen presentation and process-related CAFS and establishes a predictive signature in prostate cancer.
Wang W; Li T; Xie Z; Zhao J; Zhang Y; Ruan Y; Han B
J Transl Med; 2024 Jan; 22(1):57. PubMed ID: 38221616
[TBL] [Abstract][Full Text] [Related]
15. Prognostic value of novel immune-related genomic biomarkers identified in head and neck squamous cell carcinoma.
Yao Y; Yan Z; Lian S; Wei L; Zhou C; Feng D; Zhang Y; Yang J; Li M; Chen Y
J Immunother Cancer; 2020 Jul; 8(2):. PubMed ID: 32719094
[TBL] [Abstract][Full Text] [Related]
16. Mitochondrial DNA methylation is a predictor of immunotherapy response and prognosis in breast cancer: scRNA-seq and bulk-seq data insights.
Ma Y; Du J; Chen M; Gao N; Wang S; Mi Z; Wei X; Zhao J
Front Immunol; 2023; 14():1219652. PubMed ID: 37457713
[TBL] [Abstract][Full Text] [Related]
17. DNA methylation regulates TIGIT expression within the melanoma microenvironment, is prognostic for overall survival, and predicts progression-free survival in patients treated with anti-PD-1 immunotherapy.
Niebel D; Fröhlich A; Zarbl R; Fietz S; de Vos L; Vogt TJ; Dietrich J; Sirokay J; Kuster P; Saavedra G; Ramírez Valladolid S; Hoffmann F; Strieth S; Landsberg J; Dietrich D
Clin Epigenetics; 2022 Apr; 14(1):50. PubMed ID: 35410311
[TBL] [Abstract][Full Text] [Related]
18. Tumour microenvironment-based molecular profiling reveals ideal candidates for high-grade serous ovarian cancer immunotherapy.
Lu X; Ji C; Jiang L; Zhu Y; Zhou Y; Meng J; Gao J; Lu T; Ye J; Yan F
Cell Prolif; 2021 Mar; 54(3):e12979. PubMed ID: 33522069
[TBL] [Abstract][Full Text] [Related]
19. Adipose methylome integrative-omic analyses reveal genetic and dietary metabolic health drivers and insulin resistance classifiers.
Christiansen C; Tomlinson M; Eliot M; Nilsson E; Costeira R; Xia Y; Villicaña S; Mompeo O; Wells P; Castillo-Fernandez J; Potier L; Vohl MC; Tchernof A; Moustafa JE; Menni C; Steves CJ; Kelsey K; Ling C; Grundberg E; Small KS; Bell JT
Genome Med; 2022 Jul; 14(1):75. PubMed ID: 35843982
[TBL] [Abstract][Full Text] [Related]
20. Identification of Prognostic DNA Methylation Signatures in Lung Adenocarcinoma.
Wang P; Xu G; Gao E; Xu Y; Liang L; Jiang G; Duan L
Oxid Med Cell Longev; 2022; 2022():8802303. PubMed ID: 35814273
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
